$Cellectis (CLLS.US)$ Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting Monday, 28th April at 4:30 pm NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advan...
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Cellectis Stock Forum
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
Monday, 28th April at 4:30 pm
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advan...
No comment yet